上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-033 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 担保对象及基本情况 | 资产负债率为 | | 70%以上的全资及控股子公司 | | | | | --- | --- | --- | --- | --- | --- | | 担 保 | 对 | 被担保人名称 | | 杭州润达医疗管理有限公司 | | | | | 本次担保金额 | 16,592 | 万元 | | | 象一 | | 实际为其提供的担保余额 | 166,607.44 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 ...

Group 1 - The company's主体信用等级 is maintained at "AA" with a stable rating outlook [1][2] - The credit ratings for the issued "润达转债" and "23 润达医疗 MTN001" are also maintained at "AA" [1][2] - The credit rating agency, 新世纪评估, conducted a comprehensive analysis of the company's industry and operational status before confirming the ratings [2]

Core Viewpoint - The company, Shanghai RunDa Medical Technology Co., Ltd., is positioned well in the in-vitro diagnostic (IVD) market, benefiting from strong demand driven by economic growth, aging population, and upgrading medical consumption structure [1][3][6]. Company Overview - RunDa Medical focuses on the IVD sector, establishing a nationwide business layout and accumulating a significant customer and supplier base [1][3]. - The company has introduced state-owned capital as a controlling shareholder, enhancing its financial channels and collaboration with public healthcare institutions [3][6]. Market Environment - The IVD market is characterized by strong demand due to factors such as economic growth, an aging population, and increased healthcare spending [6][8]. - The industry faces challenges from regulatory changes and intense competition, which may impact revenue and profitability [3][6][8]. Financial Performance - The company's revenue has shown a decline, with total revenue for 2024 at 83.06 billion, down from 91.40 billion in 2023, reflecting a 9.13% decrease [8][9]. - The gross profit margin has also decreased, with a comprehensive gross margin of 25.37% in 2024 compared to 26.58% in 2023 [8][9]. Business Operations - RunDa Medical operates two main business segments: commercial comprehensive services and industrial services, with the commercial segment contributing over 90% of total revenue [10][12]. - The company has expanded its service offerings to include AI medical solutions, collaborating with major hospitals and healthcare institutions [9][10]. Competitive Position - The company has established a robust supply chain with over 1,200 suppliers and nearly 19,000 product varieties, ensuring comprehensive coverage of the IVD market [19][20]. - RunDa Medical's focus on R&D in IVD products and digital solutions positions it competitively within the industry [20]. Future Outlook - The company anticipates stable credit quality in the coming months, although potential downgrades may occur due to significant performance deterioration or changes in major stakeholders [3][4]. - Continued investment in AI and digital health solutions is expected to enhance market competitiveness and operational efficiency [9][10].

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-031 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于"润达转债"与"23 润达医疗 MTN001" 2025 年跟踪评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司前次主体信用评级结果为"AA"，评级展望为"稳定"。"润达转债"前次评 级结果为"AA"，评级时间为 2024 年 6 月 26 日。"23 润达医疗 MTN001"前次评级 结果为"AA "，评级时间为 2024 年 6 月 26 日。评级机构均为新世纪评估。 新世纪评估在对公司所属行业及经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 25 日出具了《上海润达医疗科技股份有限公司及其发行的润达转债与 23 润达医疗 MTN001 定期跟踪评级报告》【新世纪跟踪（2025）100175】，维持公司"AA" 的主体信用等级，评级展望维持"稳定"，同时维持"润达转 ...

内部编号:2025060241 上海润达医疗科技股份有限公司 及其发行的润达转债与 23 润达医疗 MTN001 定期跟踪评级报告 | 项目负责人: 能 腔 | Rectif | xh@shxs j. com | | --- | --- | --- | | 嵇敏珍 项目组成员: | 2222000 | jiminzhen@shxsj.com | | 张明海 评级总监: | 82-16 | | | 联系电话:(021)63501349 | | | | 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 | | | | 公司网站:www.shxsj.com | | | 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co., Ltd. 声明 除因本次评级事项使本评级机构与评级对象构成委托关系外,本评级机构、评级人员与评级对象不存在任何影响 评级行为独立、客观、公正的关联关系。 本评级机构与评级人员履行了调查和诚信义务，所出具的评级报告遵循了真实、客观、公正的原则。 本报告的评级结论是本评级机构依据合理的内部信用 ...

" 盘古大模型通用AI底座+润医医疗大模型，树立了AI+医疗新标 杆。 " 编辑丨 李希 | OpenCompans 1 MedBench | 精页 | 评测数据集 | 评测榜曲 | 社区舞站 文描 | | ( . 查科杯) Special Track. | | | | | | | 电 ●加入评测 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | MedBench | 评测频单 | 白测线单 | 官方自建榜单 | | | | | | | | | | MedBench如何定义得分? | | MedBench 评测榜单展示通过API盟交方式获得的评测结果 MedBench 日测榜单属示通过模型管家上纳方式获得的汗测达集 MedBench 育方自温榜单展示行业领先大赞型评测获得的结果供参考 语注意,这三个榜单所涉及的评测数据并不相同 | | | | | | | | | | | | | | | 点击查看MedBench评测历史榜单 | | | | | | | | | | | | | | | ...

Core Viewpoint - The company plans to increase the estimated amount of daily related party transactions for 2025 due to business development needs, ensuring that this will not affect its independence or reliance on related parties [1][2]. Group 1: Increase in Related Party Transactions - The company intends to increase the estimated amount of daily related party transactions for 2025 from 500 million RMB to 6.9 billion RMB, primarily due to new product demands from a related party, Guorun Medical Supply Chain Service (Shanghai) Co., Ltd [1]. - The increase in related party transactions has been approved by the board of directors and does not require shareholder meeting approval [1]. Group 2: Related Party Information - Guorun Medical Supply Chain Service (Shanghai) Co., Ltd is a subsidiary of a company in which the company holds shares, and it specializes in providing comprehensive services for medical laboratories [1]. - As of December 31, 2024, Guorun Supply Chain had total assets of 2.44 billion RMB and net assets of 734.38 million RMB, with an annual revenue of 1.00 billion RMB [1]. Group 3: Transaction Purpose and Impact - The related party transactions are necessary for the company's normal business operations and are conducted on fair and voluntary terms, ensuring no harm to the interests of the company or its shareholders [2]. - The pricing policy for these transactions is based on market fair prices, and they do not significantly impact the company's assets or profit situation [2].

一、募集资金基本情况 证券代码：603108 证券简称：润达医疗 公告编号：临 2025-029 转债代码：113588 转债简称：润达转债 上海润达医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次使用闲置募集资金暂时补充流动资金的金额不超过 16,000 万元； ●使用期限：自公司董事会审议批准之日起不超过 12 个月。 公司于 2025 年 6 月 13 日召开了第五届董事会第二十三次会议和第五届监事 会第十六次会议审议通过了《关于使用闲置募集资金暂时补充流动资金的议案》， 同意公司使用闲置募集资金不超过 16,000 万元暂时补充流动资金，使用期限自 董事会审议批准之日起不超过 12 个月。现将相关事宜公告如下： 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586号）核准，同意上海润达 医疗科技股份有限公司（以下简称"公司"或"润达医疗"）向社会公开发行面 值总额55,000.00万元可转换公司债券，期限6 ...

国金证券股份有限公司 关于上海润达医疗科技股份有限公司 使用闲置募集资金暂时补充流动资金的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技股 份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的保荐机 构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所上市公司自律监 管指引第 12 号——可转换公司债券》等相关规定，对润达医疗不提前赎回"润达 转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、募集资金基本情况 公司《公开发行可转换公司债券募集说明书》披露的募集资金项目以及截至 拟使用募集资金金额 已累计投资金额 序号 项目 | | | 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586 号）核准，同意润达医疗 向社会公开发行面值总额 55,000.00 万元可转换公司债券，期限 6 年，共计募集 资金 550,000,000.00 元，扣除承销费用 9,900,000.00 元（不含增值税）后实际收 到的金额为 540,100,000.00 元，上述款项已由主承销商国金证券股 ...

国金证券股份有限公司 | 序号 | 项目 | 拟使用募集资金金额 | 已累计投资金额 | | --- | --- | --- | --- | | | | （万元） | （万元） | | 1 | 综合服务扩容项目 | 55,000.00 | 34,115.38 | | | 合计 | 55,000.00 | 34,115.38 | 关于上海润达医疗科技股份有限公司 使用闲置募集资金暂时补充流动资金的核查意见 国金证券股份有限公司（以下简称"本保荐机构"）作为上海润达医疗科技股 份有限公司（以下简称"润达医疗"、"公司"）公开发行可转换公司债券的保荐机 构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所上市公司自律监 管指引第 12 号——可转换公司债券》等相关规定，对润达医疗不提前赎回"润达 转债"事项进行了认真、审慎的核查。核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准上海润达医疗科技股份有限公司公开 发行可转换公司债券的批复》（证监许可【2020】586 号）核准，同意润达医疗 向社会公开发行面值总额 55,000.00 万元可转换公司债券，期限 6 年，共计募集 资金 ...